{"name":"Istituto Oncologico Veneto IRCCS","slug":"istituto-oncologico-veneto-irccs","ticker":"","exchange":"","domain":"","description":"","hq":"","founded":0,"employees":"","ceo":"","sector":"","stockPrice":0,"stockChange":0,"stockChangePercent":0,"marketCap":"","metrics":{"revenue":0,"revenueGrowth":0,"grossMargin":0,"rdSpend":0,"netIncome":0,"cash":0,"dividendYield":0,"peRatio":0,"fiscalYear":"FY2026"},"revenueBreakdown":[],"timeline":[{"date":"2026-07-28","label":"Q2 2026 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2026-10-28","label":"Q3 2026 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-01-28","label":"Q4 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-04-28","label":"Q1 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-07-28","label":"Q2 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-10-28","label":"Q3 2027 Earnings","type":"earnings","sentiment":"neutral"}],"diseaseAreas":[{"name":"Oncology","slug":"oncology","revenue":0,"percentOfTotal":0,"drugCount":4,"colorKey":"oncology","drugs":[{"name":"MSB0010718C","genericName":"MSB0010718C","slug":"msb0010718c","indication":"Melanoma (in combination with checkpoint inhibitors)","status":"phase_3"},{"name":"Adjuvant Hormone Therapy","genericName":"Adjuvant Hormone Therapy","slug":"adjuvant-hormone-therapy","indication":"Breast cancer, hormone receptor-positive","status":"phase_2"},{"name":"Anti-B-RAF","genericName":"Anti-B-RAF","slug":"anti-b-raf","indication":"Metastatic melanoma with a V600E mutation","status":"phase_2"},{"name":"Local Standard of Care","genericName":"Local Standard of Care","slug":"local-standard-of-care","indication":"Various cancers as per institutional standard treatment protocols","status":"marketed"}]}],"pipeline":[{"name":"MSB0010718C","genericName":"MSB0010718C","slug":"msb0010718c","phase":"phase_3","mechanism":"MSB0010718C is a therapeutic cancer vaccine designed to activate the immune system against tumor-associated antigens.","indications":["Melanoma (in combination with checkpoint inhibitors)","Non-small cell lung cancer (in combination with checkpoint inhibitors)"],"catalyst":""},{"name":"Adjuvant Hormone Therapy","genericName":"Adjuvant Hormone Therapy","slug":"adjuvant-hormone-therapy","phase":"phase_2","mechanism":"Adjuvant Hormone Therapy involves the use of hormone-blocking medications to prevent the growth and spread of cancer cells.","indications":["Breast cancer, hormone receptor-positive"],"catalyst":""},{"name":"Anti-B-RAF","genericName":"Anti-B-RAF","slug":"anti-b-raf","phase":"phase_2","mechanism":"Anti-B-RAF drugs target and inhibit the B-Raf protein, which is often mutated in cancer cells.","indications":["Metastatic melanoma with a V600E mutation","Other cancers with B-Raf mutations"],"catalyst":""},{"name":"Local Standard of Care","genericName":"Local Standard of Care","slug":"local-standard-of-care","phase":"marketed","mechanism":"Local Standard of Care refers to the established treatment protocols and therapeutic approaches used at Istituto Oncologico Veneto IRCCS for cancer management, which vary by tumor type and patient characteristics.","indications":["Various cancers as per institutional standard treatment protocols"],"catalyst":""}],"recentEvents":[],"realNews":[],"patents":[],"drugCount":4,"phaseCounts":{"phase_3":1,"phase_2":2,"marketed":1},"enrichmentLevel":2,"visitCount":3,"keyCompetitors":[],"therapeuticFocus":[],"financials":null,"yahoo":null}